Fritextsökning
Innehållstyper
-
Pharma Relations AB
-
The new Swedish life science strategy – “It will consolidate Sweden as a leader”
Clinical trials and precision health are emphasised as key areas in the new national life science strategy.
-
Merck Life Science A/S
-
Compact and leak-tight powerhouse
Media-separated solenoid valve VYKA from Festo is virtually leak-free
-
New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)
-
Are you ready for EMC 2024?
Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.
-
Heidi Stensmyren is eager for new challenges in the biotech industry
Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Dir...
-
Quotient Sciences Limited
-
Bio-Works
-
Superconductor technology: Contactless working in the laboratory of the future
Automated filling and weighing of freeze-dry containers in the cleanroom with SupraMotion from Festo
-
Affibody AB
-
Introducing ZEISS arivis Pro 4.2
ZEISS arivis software enhances custom microscopy image analysis.
-
Novo Nordisk to invest billions in new quality control lab
Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.
-
Reliably gripping and turning small parts
The extremely compact rotary gripper module EHMD is the ideal choice in many life science applications where small objects need to be gripped and turned in conf...
-
Medicon Valley Alliance
-
Aurevia
-
Don't miss out on this unique opportunity
ZEISS QUALITY INNOVATION SUMMIT October 22 - 24 in Berlin.
-
Helena Strigård: The rise of the community
Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.
-
GSK acquires oncology research company
GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
“We need to build flexible operating theatres”
Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas ...
-
Danish obesity success causes recruitment problems in southern Sweden
The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.
-
600 million SEK for life science - "Should not be the country of moderation"
Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.
-
Looking for greater Nordic cooperation – “We have Norway and Finland in our sights”
How can Medicon Valley Alliance bring the big pharmaceutical companies back to the organisation? Life Science Sweden discussed this topic and others with the cl...